The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Nektar sells Huntsville manufacturing plant to Ampersand in $90M partnership deal
Nov 04, 2024•over 1 year ago
Contract Type
partnership
San FranciscoBiotechnologyHealth Care
Description
Nektar Therapeutics has announced the sale of its Huntsville, Alabama, manufacturing plant and reagent supply business to private equity firm Ampersand Capital Partners for a total value of $90 million. As part of the agreement, Nektar will receive $70 million in cash and a $20 million equity position in a new Ampersand portfolio company. The partnering companies also plan to forge manufacturing supply agreements to meet Nektar's PEG reagent needs for its lead candidate rezpegaldesleukin and certain other pipeline assets, aiming to focus on the development of new therapeutics for immunology.
Company Information
Company
Nektar Therapeutics
Location
San Francisco, California, United States
About
Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and viral diseases. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new drug candidates.
San FranciscoBiotechnologyHealth Care